Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed non-Hodgkin's lymphoma OR primary or metastatic solid tumor located in at least one of the following sites:
• •* Liver
• •* Soft tissue
• •* Pelvis
• •* Other site that is suitable for delayed contrast-enhancing MRI
• •Relapsed or refractory disease
• •* Failed all conventional therapeutic options AND not amenable to existing therapeutic options
• •Must have completed the active phase (through study visit 9) of MSKCC-03137 (VGFT-ST-0202) without experiencing dose-limiting toxicity
• •No prior or concurrent CNS metastases (brain or leptomeningeal)
• •* No new neurological symptoms during treatment on MSKCC-03137 (VGFT-ST-0202)
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •Not specified
• •Life expectancy
• •Not specified
• •Hematopoietic
• •No severe or uncontrolled hematologic condition
• •Hepatic
• •Not specified
• •Renal
• •No severe or uncontrolled renal condition
• •Cardiovascular
• •No severe or uncontrolled cardiovascular condition
• •Pulmonary
• •No severe or uncontrolled pulmonary condition
• •Other
• •No severe or uncontrolled gastrointestinal, immunologic, or musculoskeletal condition
• •No other medical or psychiatric condition or adverse social circumstance that would preclude study participation
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective double-barrier contraception during and for 3 months after study treatment
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)
• •Chemotherapy
• •Not specified
• •Endocrine therapy
• •No concurrent adrenal corticosteroids, except low-dose replacement therapy
• •No concurrent systemic hormonal contraceptive agents
• •Radiotherapy
• •Not specified
• •Surgery
• •Not specified
• •Other
• •No concurrent non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 (COX-2) inhibitors
• •No concurrent anticoagulant or antiplatelet drugs, including warfarin, heparin, or aspirin
• •* Concurrent low-dose (i.e., 1 mg) warfarin for maintaining patency of venous access devices allowed
• •No other concurrent standard or investigational agents for this malignancy